Much-Hyped Renal Denervation Devices Could Help Diabetics, Too

Source: Fierce Medical Devices, Damian Garde (10/5/12)

"Renal denervation devices, designed to treat hypertension, are already tabbed for big sales in that sphere--$2.8 billion by 2020, analysts say. Now, new research suggests the nerve-deadening procedure could benefit diabetics, an even larger patient population."

Fierce Medical Devices, Damian Garde

Renal denervation devices, designed to treat hypertension, are already tabbed for big sales in that sphere--$2.8 billion by 2020, analysts say. Now, new research suggests the nerve-deadening procedure could benefit diabetics, an even larger patient population.

As MedPage Today reports, scientists at the European Association for the Study of Diabetes meeting in Berlin said renal denervation has shown promise to improve insulin and glucose levels in diabetics in small, early trials. The treatment also reduced levels in C-peptide, a marker of beta-cell function, according to Felix Mahfoud of Saarland University in Germany. . .View Full Article

Biotech Boasts Compelling Pipeline
Source: Dr. Andre Uddin (06/23/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report.

Analyst Shares Thoughts After Microdisplay Co.'s Demo Day
Source: Jaeson Schmidt (06/23/2025)

Kopin Corp.'s (KOPN:NASDAQ) display and optical technologies as well as its products are impressive, noted a Lake Street Capital Markets report.

Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)

Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.